However, studies on off-label use of monoclonal antibodies (MCAs), including tocilizumab (IL-6 inhibitor), secukinumab (IL-17A inhibitor), sotrovimab (binds with spike protein of SARS-CoV-2), bamlanivimab (binds with spike protein of SARS-CoV-2), baricitinib (janus kinase (JAK) inhibitor that block JAK-1 and JAK-2), and so on in COVID-19 have demonstrated promising outcome in mortality reduction and prevention of MV but therapeutic safety and efficacy data are limited [15–17]. Here, IL17A is linked to COVID-19.